Real Ohio

Real Ohio for Real Ohioans

← Back to the latest stories

Real news about Real Ohioans · 2026-09-03 · Athens, Ohio

FDA Approves First-Ever Treatment for Alexander Disease, and an Athens Lab Erupts

For the first time ever, Alexander disease has an FDA-approved treatment — and one Ohio University lab in Athens celebrated like the Bobcats just beat Ohio State.

What actually happened

The U.S. Food and Drug Administration on September 3, 2026 approved Zanvastro (zilganersen) injection for the treatment of Alexander disease in pediatric and adult patients. It is the first FDA-approved treatment for Alexander disease and the first therapy to directly target the protein buildup that drives the disease.

Alexander disease is a rare, progressive neurological disorder caused by mutations in the gene that produces glial fibrillary acidic protein, or GFAP. When the protein is abnormal, it accumulates in the brain's supportive cells, causing damage to the nervous system over time. The disease affects less than 1 in a million people and can cause seizures, loss of developmental milestones, difficulty walking, muscle weakness, and increased pressure in the brain. Until now, patients had no approved treatment options, only supportive care.

Zanvastro is an antisense oligonucleotide that reduces production of the abnormal GFAP protein before it can accumulate. It is given as an injection into the spinal canal every three months by a trained health care professional. In a multicenter, randomized, controlled study of 49 patients aged 2 and older, patients aged 5 and up with walking difficulties who received Zanvastro showed significantly better walking speed at 61 weeks than those who received no treatment. The approval was granted to Ionis Pharmaceuticals, and the drug received Orphan Drug, Fast Track, Breakthrough Therapy, and Rare Pediatric Disease designations.

FDA Approves First-Ever Treatment for Alexander Disease, and an Athens Lab Erupts

Meanwhile, in Ohio

ATHENS, Ohio — Molly Delaney was three coffees deep into a Thursday afternoon in her Ohio University neuroscience lab when the email arrived: the Food and Drug Administration had approved Zanvastro, the first treatment ever cleared for Alexander disease, a rare and progressive neurological disorder caused by a faulty protein called GFAP — the very protein Molly has spent four years studying under a microscope on the bricks of the Athens campus. She read the announcement twice, stood up, and announced to the lab that she was buying everyone dinner on Court Street.

"People hear 'rare disease' and they think it doesn't matter, because it's only a few hundred people," Molly said, still wearing her lab coat at the counter of a Court Street diner that evening. "But for those families, there has never been anything. Not one approved drug. Just supportive care while the disease gets worse. And now there's a drug that goes after the actual protein causing the damage. That's not a small thing. That's the whole thing." Her father Frank, a retired high school football coach from the Athens area, drove in from the county fairgrounds, where he had been setting up a booth, to join the celebration. "She tried to explain the science to me once," he said. "I understood about every fourth word. I understood this one, though: first treatment ever."

Back in the lab on Friday, Molly taped a printout of the FDA announcement to the wall next to a Bobcats schedule and a photo of her cohort at last fall's homecoming parade. The drug, made by Ionis Pharmaceuticals, is given as an injection into the spinal canal every three months, and in the pivotal trial patients who received it kept their walking speed far better than those who went untreated. "Nobody in this lab cured anything," Molly said. "But somebody, somewhere, spent ten years turning this protein from a mystery into a medicine, and today they got to watch the FDA say yes. Around here, that is worth at least one very loud dinner on Court Street."

FDA Approves First-Ever Treatment for Alexander Disease, and an Athens Lab Erupts

“Four years I have stared at GFAP under a microscope, and my own mother still thinks I study geckos. Today, for the first time, I got to call her and say, 'Mom, it worked. Somebody's kid gets a drug because of this protein.'”

— Molly Delaney, Athens

“She texted me a link to the FDA announcement and then just the words 'IT'S REAL' in all caps, and I have never been prouder, even if I still have no idea what a glial fibrillary acidic protein is.”

— Frank Delaney, Athens